company background image
DNTH logo

Dianthus Therapeutics NasdaqCM:DNTH Stock Report

Last Price

US$23.99

Market Cap

US$710.0m

7D

2.3%

1Y

153.9%

Updated

02 Dec, 2024

Data

Company Financials +

Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$710.0m

Dianthus Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dianthus Therapeutics
Historical stock prices
Current Share PriceUS$23.99
52 Week HighUS$33.77
52 Week LowUS$6.58
Beta0
11 Month Change-14.35%
3 Month Change-13.24%
1 Year Change153.86%
33 Year Changen/a
5 Year Changen/a
Change since IPO118.09%

Recent News & Updates

Recent updates

Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Jul 03
Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

DNTHUS BiotechsUS Market
7D2.3%1.6%0.6%
1Y153.9%15.3%31.9%

Return vs Industry: DNTH exceeded the US Biotechs industry which returned 15.3% over the past year.

Return vs Market: DNTH exceeded the US Market which returned 31.9% over the past year.

Price Volatility

Is DNTH's price volatile compared to industry and market?
DNTH volatility
DNTH Average Weekly Movement8.8%
Biotechs Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: DNTH has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DNTH's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201953Marino Garciadianthustx.com

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc. Fundamentals Summary

How do Dianthus Therapeutics's earnings and revenue compare to its market cap?
DNTH fundamental statistics
Market capUS$710.03m
Earnings (TTM)-US$67.09m
Revenue (TTM)US$5.37m

132.3x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DNTH income statement (TTM)
RevenueUS$5.37m
Cost of RevenueUS$0
Gross ProfitUS$5.37m
Other ExpensesUS$72.46m
Earnings-US$67.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.27
Gross Margin100.00%
Net Profit Margin-1,250.32%
Debt/Equity Ratio0%

How did DNTH perform over the long term?

See historical performance and comparison